More drugs, vaccines needed for M/XDR-TB

8 April 2009

Health ministers from countries with the greatest burdens of multiple or extreme drug-resistant tuberculosis (M/XDR-TB) have agreed a program to  halt and reverse the global disease epidemic. The leaders met in  Beijing, China, at a three-day event hosted by the World Health  Organization's Director General Margaret Chan and the co-chairman of the  Bill & Melinda Gates Foundation, Microsoft founder Bill Gates. China's  Vice Premier Li Keqiang and representatives of 27 countries with high  burdens of TB were also present.

A package of measures was called for, including: universal access to  M/XDR-TB diagnosis and treatment by 2015; removal of financial barriers  to TB care; sufficient trained and deployed staff; improved laboratory  systems; the development of airborne infection-control policies; a  sufficient supply of high-quality anti-TB drugs; and mechanisms to  ensure availability of TB medicines is regulated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight